摘要
目的:探究辛伐他汀联合尼莫地平对蛛网膜下腔出血(SAH)后脑血管痉挛(CVS)患者的影响。方法:回顾性纳入2021年9月—2023年12月武穴市中医医院神经外科收治的SAH后CVS患者77例,按照不同的治疗方式进行分组,单一组(n=38)采取尼莫地平治疗,联合组(n=39)在单一组的基础上联合辛伐他汀治疗,对比两组临床疗效、炎症因子、氧化应激指标。结果:治疗后,联合组临床总有效率(94.87%)相较单一组(78.95%)高,差异有统计学意义(P<0.05)。治疗前,两组炎症因子、氧化应激指标水平对比,差异均无统计学意义(P>0.05);治疗后,联合组炎症因子相较于单一组均低,超氧化物歧化酶(SOD)水平较单一组高,丙二醛(MDA)水平较单一组低,差异均有统计学意义(P<0.05)。结论:采取辛伐他汀联合尼莫地平治疗SAH后CVS患者,可有效促进患者病情康复,降低患者体内炎症因子,改善氧化应激水平。
Objective:To investigate the effect of Simvastatin combined with Nimodipine on patients with cerebral vascular spasm(CVS)after subarachnoid hemorrhage(SAH).Method:A total of 77 patients with CVS after SAH admitted to the Department of Neurosurgery of Wuxue Hospital of Traditional Chinese Medicine from September 2021 to December 2023 were included retrospectively and grouped in accordance with different treatment modalities,the single group(n=38)was treated with Nimodipine,and the combined group(n=39)was treated with Simvastatin on the basis of the single group.The clinical efficacy,inflammatory factors and oxidative stress indexes of the two groups were compared.Result:After treatment,the total clinical effective rate(94.87%)of the combined group was higher than that(78.95%)of the single group,the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in the levels of inflammatory factors and oxidative stress indexes between the two groups(P>0.05);after treatment,the inflammatory factors in combined group were lower than those in single group,the level of superoxide dismutase(SOD)was higher than that in single group,and the level of malondialdehyde(MDA)was lower than that in single group,the differences were statistically significant(P<0.05).Conclusion:Simvastatin combined with Nimodipine in the treatment of patients with CVS after SAH can effectively promote the rehabilitation of the patients,reduce the inflammatory factors in the patients,and improve the level of oxidative stress.
作者
郭校
吴增宝
GUO Xiao;WU Zengbao(Department of Neurosurgery,Wuxue Hospital of Traditional Chinese Medicine,Wuxue 435400,China;不详)
出处
《中国医学创新》
2025年第16期63-67,共5页
Medical Innovation of China
